Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.92 | 2.84 | 3.45 | 4.06 | 3.30 | 3.84 | 2.26 | 5.80 | 4.89 | 4.31 | 1.98 | 6.08 |
| Expenses | 3.31 | 3.42 | 3.84 | 4.56 | 3.62 | 4.24 | 2.81 | 5.62 | 4.88 | 4.32 | 2.49 | 6.04 |
| Operating Profit | -0.39 | -0.58 | -0.39 | -0.50 | -0.32 | -0.40 | -0.55 | 0.18 | 0.01 | -0.01 | -0.51 | 0.04 |
| OPM % | -13.36% | -20.42% | -11.30% | -12.32% | -9.70% | -10.42% | -24.34% | 3.10% | 0.20% | -0.23% | -25.76% | 0.66% |
| Other Income | 0.00 | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.09 | 0.09 | 0.09 | 0.09 | 0.18 | 0.14 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Profit before tax | -0.42 | -0.61 | -0.34 | -0.53 | -0.35 | -0.43 | -0.49 | 0.24 | 0.07 | 0.05 | -0.36 | 0.15 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -261.11% | 0.00% |
| Net Profit | -0.42 | -0.61 | -0.34 | -0.53 | -0.34 | -0.43 | -0.49 | 0.24 | 0.07 | 0.05 | 0.58 | 0.15 |
| EPS in Rs | -1.40 | -2.03 | -1.13 | -1.77 | -1.13 | -1.43 | -1.63 | 0.80 | 0.23 | 0.17 | 1.93 | 0.50 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 46.88 | 59.78 | 55.71 | 65.18 | 49.62 | 34.98 | 8.53 | 22.23 | 16.49 | 13.46 | 16.98 | 17.26 |
| Expenses | 45.44 | 58.53 | 53.75 | 64.01 | 48.89 | 35.58 | 10.53 | 22.53 | 17.95 | 15.23 | 17.31 | 17.73 |
| Operating Profit | 1.44 | 1.25 | 1.96 | 1.17 | 0.73 | -0.60 | -2.00 | -0.30 | -1.46 | -1.77 | -0.33 | -0.47 |
| OPM % | 3.07% | 2.09% | 3.52% | 1.80% | 1.47% | -1.72% | -23.45% | -1.35% | -8.85% | -13.15% | -1.94% | -2.72% |
| Other Income | 0.01 | 0.61 | 0.09 | 0.74 | 0.17 | 0.31 | 0.00 | 0.01 | 0.08 | 0.09 | 0.45 | 0.50 |
| Interest | 0.11 | 0.07 | 0.06 | 0.07 | 0.05 | 0.04 | 0.06 | 0.01 | 0.06 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.05 | 0.11 | 0.10 | 0.11 | 0.12 | 0.12 |
| Profit before tax | 1.31 | 1.76 | 1.96 | 1.81 | 0.82 | -0.36 | -2.11 | -0.41 | -1.54 | -1.79 | 0.00 | -0.09 |
| Tax % | 27.48% | 20.45% | 34.69% | 26.52% | 28.05% | 55.56% | -22.27% | 109.76% | -19.48% | -3.35% | ||
| Net Profit | 0.95 | 1.39 | 1.28 | 1.33 | 0.59 | -0.55 | -1.64 | -0.87 | -1.25 | -1.74 | 0.94 | 0.85 |
| EPS in Rs | 3.17 | 4.63 | 4.27 | 4.43 | 1.97 | -1.83 | -5.47 | -2.90 | -4.17 | -5.80 | 3.13 | 2.83 |
| Dividend Payout % | 31.58% | 32.37% | 23.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | -10% | -13% | -9% | 14% | ||
| Compounded Profit Growth | 0% | 30% | 46% | 183% | ||
| Stock Price CAGR | -8% | 1% | -2% | 7% | ||
| Return on Equity | -1% | -16% | -15% | 24% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| Reserves | 1.94 | 2.53 | 3.92 | 4.63 | 5.66 | 6.26 | 5.79 | 4.22 | 3.31 | 2.06 | 0.36 | 1.34 |
| Borrowings | 0.11 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 8.95 | 8.30 | 10.11 | 14.94 | 13.85 | 11.03 | 5.08 | 6.56 | 8.22 | 9.53 | 17.13 | 16.52 |
| Total Liabilities | 14.00 | 13.95 | 17.03 | 22.57 | 22.51 | 20.29 | 13.87 | 13.78 | 14.53 | 14.59 | 20.49 | 20.86 |
| Fixed Assets | 0.19 | 0.24 | 0.25 | 0.22 | 0.19 | 0.18 | 0.14 | 0.39 | 0.37 | 0.33 | 0.46 | 0.36 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 13.78 | 13.68 | 16.78 | 22.35 | 22.32 | 20.11 | 13.73 | 13.39 | 14.16 | 14.26 | 20.03 | 20.50 |
| Total Assets | 14.00 | 13.95 | 17.03 | 22.57 | 22.51 | 20.29 | 13.87 | 13.78 | 14.53 | 14.59 | 20.49 | 20.86 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0.23 | 0.05 | 1.37 | -1.54 | 0.21 | -0.08 | 0.03 | 0.19 | 0.32 | -0.03 | 0.05 | 0.77 |
| Cash from Investing Activity | -0.12 | -0.08 | 0.57 | 0.00 | 0.00 | -0.02 | 0.00 | -0.30 | -0.10 | -0.01 | -0.24 | -0.03 |
| Cash from Financing Activity | 0.00 | -0.05 | -0.11 | -0.06 | -0.06 | -0.05 | -0.04 | -0.06 | -0.01 | 0.00 | 0.00 | 0.00 |
| Net Cash Flow | 0.11 | -0.08 | 1.83 | -1.60 | 0.15 | -0.14 | 0.00 | -0.17 | 0.21 | -0.04 | -0.20 | 0.74 |
| Free Cash Flow | 0.11 | -0.03 | 1.34 | -1.54 | 0.21 | -0.10 | 0.03 | -0.11 | 0.22 | -0.04 | -0.19 | 0.74 |
| CFO/OP | 41% | 28% | 170% | -14% | 88% | 21% | -52% | -10% | -103% | 2% | -3% | -233% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 87.07 | 71.63 | 79.50 | 98.60 | 92.17 | 110.34 | 96.83 | 120.24 | 87.35 | 85.88 | 92.47 | 76.31 |
| Inventory Days | 11.17 | 4.50 | 2.59 | 2.62 | 2.12 | 3.38 | 3.16 | 261.82 | 91.20 | 153.02 | 320.33 | 253.06 |
| Days Payable | 73.72 | 44.59 | 47.70 | 83.93 | 64.58 | 74.47 | 32.34 | 224.66 | 123.19 | 144.12 | 252.10 | 362.48 |
| Cash Conversion Cycle | 24.52 | 31.54 | 34.39 | 17.29 | 29.72 | 39.25 | 67.65 | 157.41 | 55.36 | 94.78 | 160.70 | -33.11 |
| Working Capital Days | 15.87 | 18.92 | 28.21 | 43.37 | 42.06 | 58.04 | 77.53 | 241.76 | 80.62 | 137.90 | 216.40 | 35.90 |
| ROCE % | 11.91% | 26.54% | 29.28% | 27.77% | 23.08% | 9.71% | -3.55% | -25.61% | -5.91% | -25.86% | -42.52% | 0.00% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 53.72% | 53.72% | 53.64% | 53.64% | 53.64% | 53.64% | 53.66% | 53.66% | 53.66% | 53.39% | 52.94% | 52.94% |
| DIIs | 0.59% | 0.59% | 0.35% | 0.35% | 0.35% | 0.35% | 0.35% | 0.35% | 0.35% | 0.35% | 0.35% | 0.35% |
| Public | 45.69% | 45.69% | 46.02% | 46.02% | 46.02% | 46.02% | 46.01% | 46.00% | 45.99% | 46.27% | 46.72% | 46.72% |
| No. of Shareholders | 6,194 | 6,139 | 4,160 | 4,090 | 4,157 | 4,060 | 4,024 | 3,975 | 3,958 | 3,444 | 3,303 | 3,284 |
Fundamentals
Market Cap₹ 6.42 Cr.
Current Price₹ 21.4
Stock P/E7.55
Book Value₹ 14.5
ROCE0.00 %
ROE24.4 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)14%
Compounded Profit Growth (TTM)183%
Standalone figures.
Valuation
Market capRs 7 Cr
Enterprise valueRs 7 Cr
P/E (TTM)8.68x
Price to book1.70x
Price to sales0.43x
EV / EBITDA236.69x
EV / sales0.41x
Price to cash flow9.59x
Earnings yield11.52%
P/E, 3-year average6.65x
P/B, 3-year average1.36x
P/E, 5-year average6.65x
P/B, 5-year average1.12x
Profitability
Operating margin (excl. other income)-1.94%
Operating margin (incl. other income)0.71%
EBITDA margin0.17%
Pre-tax margin-0.52%
Net profit margin4.92%
Net margin, latest quarter2.47%
ROE24.42%
ROA4.55%
ROE, 3-year average-12.97%
ROCE, 3-year average-34.28%
ROA, 3-year average-4.65%
ROE, 5-year average-14.45%
ROCE, 5-year average-25.02%
ROA, 5-year average-6.39%
ROIC (approx.)-2.22%
Other income / net worth10.37%
Growth
Sales growth (latest year)26.15%
Sales CAGR, 3 years-8.59%
Sales CAGR, 5 years-13.46%
Sales growth QoQ207.07%
Profit growth QoQ-74.14%
Sales growth YoY (latest quarter)4.83%
Profit growth YoY (latest quarter)-37.50%
Per share
EPS (TTM)Rs 2.83
EPS (latest year)Rs 3.13
EPS (latest quarter)Rs 0.50
EPS, 3-year averageRs -2.28
EPS, 5-year averageRs -3.04
Book value per shareRs 14.47
Sales per shareRs 57.53
Cash flow per shareRs 2.57
Free cash flow per shareRs 2.47
Efficiency
Asset turnover0.81x
Fixed asset turnover47.17x
Inventory turnover1.46x
Inventory days250 days
Debtor days76 days
Debtors turnover4.78x
Creditor days362 days
Cash conversion cycle-33 days
Working capital days36 days
Leverage
Cash and bankRs 0 Cr
Net debtRs -0 Cr
Net debt / EBITDA-9.33x
Owners' fund to total sources20.81%
Cash flow
Cash from Operating Activity (latest year)Rs 1 Cr
Cash from Investing Activity (latest year)Rs -0 Cr
Net Cash Flow (latest year)Rs 1 Cr
Free cash flow (latest year)Rs 1 Cr
Sales to cash flow22.05x
Statement figures
Net sales (TTM)Rs 17 Cr
Net sales (latest year)Rs 17 Cr
Sales (latest quarter)Rs 6 Cr
Operating profit excl. other income (latest year)Rs -0 Cr
Operating profit (latest quarter)Rs 0 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 0 Cr
PBDT (TTM)Rs 0 Cr
Profit before tax (TTM)Rs -0 Cr
Tax (latest year)Rs -1 Cr
Net profit (TTM)Rs 1 Cr
Net profit (latest year)Rs 1 Cr
Net profit (latest quarter)Rs 0 Cr
Depreciation (TTM)Rs 0 Cr
Depreciation (latest quarter)Rs 0 Cr
Cost of goods sold (latest year)Rs 15 Cr
Total expenditure (latest year)Rs 17 Cr
Total income (latest year)Rs 17 Cr
Share capitalRs 3 Cr
ReservesRs 1 Cr
Shareholders' fundsRs 4 Cr
Total assetsRs 21 Cr
Net blockRs 0 Cr
ReceivablesRs 4 Cr
InventoryRs 10 Cr
Other liabilitiesRs 17 Cr
Shares outstanding (crore)0.30
Ownership
Promoter holding52.94% (-0.72 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 8.7 is at the 35th percentile of its own 4.5-year range
(median 10.2, low 4.2, high 21.2).
P/B 1.70 is at the 76th percentile (median 1.07).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 530207 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +7.9% | -2.8% | +10.7 pts |
| 1 month | +7.0% | -6.8% | +13.7 pts |
| 3 months | +8.4% | -7.6% | +16.0 pts |
| 3 years | +7.0% | +14.2% | -7.2 pts |
| 5 years | +20.6% | +27.9% | -7.3 pts |
Red flags
F-score 6 of 7No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹6 Cr +4.8% vs Jun 2025.
Net profit ₹0 Cr -37.5%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Brawn Biotech Ltd?
Brawn Biotech Ltd (530207) has a market capitalisation of Rs 6.42 Cr. at the 2026-10-01 close.
What is the P/E ratio of Brawn Biotech Ltd?
Brawn Biotech Ltd trades at a P/E of 7.55 on trailing twelve-month profit, at the 2026-10-01 close.
What were Brawn Biotech Ltd's latest quarterly results?
In the Jun 2026 quarter, Brawn Biotech Ltd sales was Rs 6 Cr (+4.8% vs Jun 2025) and net profit was Rs 0 Cr.